Article
The panel members discuss the question of how much would it cost to abolish the SGR.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Unpacking the Complexity of the Most Favored Nation Mandate
Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen
340B Program Spending Increases Due to Market Trends and Eligibility Expansion
High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management
Employers Eye Transparency, Data Access to Confront Rising Health Care Costs
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says